Tamarind Bio · Feb 2026
Company blog announcing a $13.6M total raise, including a $12M Series A led by Dimension Capital with participation from Y Combinator, plus customer traction and product positioning.
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Tamarind Bio is an AI infrastructure platform for biotech R&D that gives scientists a web interface, API, and CLI to run computational biology and molecular AI models at scale for drug discovery and related research.
Primary product
A central web platform and programmatic API for running 250+ computational biology and physics-based models (plus CLI/MCP access) for protein, peptide, enzyme, antibody, and small-molecule design.
Founded
2023
Headquarters
San Francisco, California, United States
Team size
11-50 employees
Work style
Onsite
Industry
Software Development
Sub-industry
AI infrastructure / computational biology platform for biotech R&D
7 jobs at Tamarind Bio
Offices
Business model
Stage
Series A
Total raised
$13.6M
Latest round
Series A · Feb 2026
Latest amount
$12M
Feb 2026 · Dimension Capital
Apr 2024 · Y Combinator
Jan 2024
Leadership
Co-Founder & CEO
Co-Founder & CTO
Ira Wight
team member
Founding Software Engineer
Investors
Founder-led, technical, customer-close, and research-focused; hiring emphasizes hard technical problems, backend/infra, and protein engineering, with close work alongside customers.
Work style
Onsite
Visa sponsorship
Limited
Compensation
Public job postings show salary bands such as $150K-$250K for founding software engineer roles and $130K-$200K for scientist roles, with some roles explicitly limited to US citizen/visa holders.
Benefits
Pricing
Tiered pricing with Free, Premium, and Enterprise plans, plus an extended Academic Plan.
Differentiators
Technology
Customers
Competitors
Estimated revenue
Unknown; public estimate sources conflict and are not company-confirmed
Estimated monthly visits
62.9K
Traffic estimate as of Jun 2026
Tamarind Bio · Feb 2026
Company blog announcing a $13.6M total raise, including a $12M Series A led by Dimension Capital with participation from Y Combinator, plus customer traction and product positioning.
Forbes · Feb 2026
Profiles the company, its cash-flow-positive status, growth, and customer adoption across pharma and biotech.
Genetic Engineering & Biotechnology News · Feb 2026
Independent coverage of the Series A, including the company's origin story, product scope, and Dimension Capital's lead role.
BioPharmaTrend · Feb 2026
Coverage of the financing and platform usage across biotech organizations, with customer adoption claims and model-library expansion.
Y Combinator
YC profile with founding year, headquarters, team size, founders, and product description.